Amgen Inc was incorporated in the State of Delaware on October 31, 1986. It is a biotechnology company that discovers, develops, manufactures and delivers human therapeutics. It operates in one business segment being human therapeutics. Its Cardiovascular products include Repatha, Corlanor, Inflammation products include Brodalumab, Nephrology, Oncology products include BLINCYTO, Kyprolis, Neulasta, Rilotumumab, Talimogene laherparepvec, Trebananib, Biosimilars, among others. Its geographic areas of operations include USA, Europe and Canada. Certain raw materials, medical devices and components necessary for the commercial and/or clinical manufacturing of the Company's products are provided by and are the proprietary products of unaffiliated third-party suppliers, certain of which may be its only sources for such materials. The Company's sales and marketing forces are mainly located in the United States and Europe. Together with its partners, the Company markets its products to healthcare providers, including physicians or their clinics, dialysis centers, hospitals and pharmacies. In the United States, the Company sells primarily to pharmaceutical wholesale distributors. The Company's competitors include Teva Pharmaceutical Industries Ltd., Janssen Biotech, Inc., AbbVie Inc., Merck & Company, Inc., Novartis AG, F. Hoffmann-La Roche Ltd., Eli Lilly/Bristol-Myers Squibb Company, Merck KGaA, Genentech, Inc., GlaxoSmithKline PLC, Millennium Pharmaceuticals, Inc., and Celgene Corporation. Some of the Company's patents include Neulasta, NEUPOGEN, Enbrel, XGEVA, Prolia, EPOGEN, Aranesp, Sensipar, Mimpara, Kyprolis, Nplate, Vectibix, and BLINCYTO. The Company's business has been and will continue to be subject to various other U.S. and foreign laws, rules and/or regulations.